Olanzapine and Samidorphan

Brand names: Lybalvi · Active ingredient: Olanzapine, Samidorphan L-Malate

In short: LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment

Forms & strengthsLYBALVI tablets are available in four strengths (Table 1). Tablet Strength | Tablet Color/Shape | Tablet Markings 5 mg/10 mg (olanzapine/samidorphan) | Yellow, capsule-shaped | “OS” and “5” 10 mg/10 mg (olanzapine/samidorphan) | Orange, capsule-shaped | “OS” …
LabelAlkermes, Inc.
Label updatedFeb 16, 2026

What is Olanzapine and Samidorphan used for?

LYBALVI is indicated for the treatment of:

Schizophrenia in adults

Bipolar I disorder in adults

Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate

Maintenance monotherapy treatment

⚠ Boxed warning (FDA's strongest warning)

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis

.

Olanzapine and Samidorphan dosage

LYBALVI is contraindicated in patients using opioids or undergoing acute opioid withdrawal.

In patients who use opioids, delay initiation of LYBALVI for a minimum of 7 days after last use of short-acting opioids and 14 days after last use of long-acting opioids .

Initiate LYBALVI at 5 mg/10 mg (contains 5 mg of olanzapine and 10 mg of samidorphan) or 10 mg/10 mg (contains 10 mg of olanzapine and 10 mg of samidorphan) orally once daily. The recommended dosage is 10 mg/10 mg, 15 mg/10 mg (contains 15 mg of olanzapine and 10 mg of samidorphan), or 20 mg/10 mg (contains 20 mg of olanzapine and 10 mg of samidorphan) once daily.

Dosage may be adjusted at weekly intervals of 5 mg (based on the olanzapine component of LYBALVI) depending upon clinical response and tolerability, up to the maximum recommended dosage of 20 mg/10 mg once daily.

Monotherapy: Initiate LYBALVI at 10 mg/10 mg or 15 mg/10 mg once daily. The recommended dosage is 10 mg/10 mg, 15 mg/10 mg, or 20 mg/10 mg once daily. The maximum recommended dosage is 20 mg/10 mg once daily.

Dosage adjustments should occur at intervals of not less than 24 hours. When dosage adjustments are necessary, dose increments/decrements of 5 mg (based on the olanzapine component of LYBALVI) are recommended.

Maintenance Monotherapy: Administer LYBALVI at 5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg, or 20 mg/10 mg once daily.

Adjunctive to lithium or valproate: Initiate LYBALVI at 10 mg/10 mg once daily. The recommended dosage is 10 mg/10 mg, 15 mg/10 mg or 20 mg/10 mg, once daily.

Dosage may be adjusted at weekly intervals of 5 mg (based on the olanzapine component of LYBALVI), depending upon clinical response and tolerability, up to the maximum recommended dosage of 20 mg/10 mg once daily.

Administer LYBALVI orally once daily with or without food as a single tablet.

Do not divide tablets or combine strengths.

The recommended starting dosage of LYBALVI is 5 mg/10 mg once daily in patients who have a higher risk of hypotensive reactions, are at risk of slower olanzapine metabolism, or may be more pharmacodynamically sensitive to olanzapine [see Warnings and Precautions (5.9), Drug Interactions (7.2), Use in Specific Populations (8.5), and Clinical Pharmacology (12.3)]. If dose escalation is necessary, increase the dosage slowly in these patients.

How to take Olanzapine and Samidorphan — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Concomitant Use with Opioids is Contraindicated

Advise patients to inform their healthcare provider if they are taking, or plan to take any opioids for any reason, as LYBALVI is contraindicated with use of opioids or those undergoing acute opioid withdrawal [see Dosage and Administration (2.1), Contraindications (4), Warnings and Precautions (5.3), Drug Interactions (7.3)].

Precipitation of Opioid Withdrawal

Advise patients not to take LYBALVI when using opioids because of the risks of opioid withdrawal syndrome, sometimes requiring hospitalization. Advise patients that they should have an opioid-free period of a minimum of 7 days after last use of short-acting opioids and 14 days from last use of long-acting opioids before initiating LYBALVI .

Risk of Opioid Overdosage

Advise patients that they may be at increased risk of opioid overdosage if they attempt to use high or repeated opioid doses. Inform patients of the potential consequences of trying to overcome the opioid blockade and the serious risks of taking opioids concurrently with LYBALVI or while transitioning off LYBALVI . …

Warnings & precautions

Do not take this medicine if: LYBALVI is contraindicated in patients:

who are using opioids .

who are undergoing acute opioid withdrawal .

If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products .

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In placebo-controlled clinical trials of elderly patients with dementia-related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than in placebo-treated patients (3.5% vs 1.5%, respectively). Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. LYBALVI is not approved for the treatment of patients with dementia-related psychosis .

Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse reactions in patients treated with olanzapine compared to patients treated with placebo. LYBALVI is not approved for the treatment of patients with dementia-related psychosis . …

Olanzapine and Samidorphan side effects

The following adverse reactions are discussed in detail in other sections of the labeling:

Increased Mortality in Elderly Patients with Dementia-related Psychosis

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis

Precipitation of Opioid Withdrawal in Patients Who Are Dependent on Opioids

Vulnerability to Life-Threatening Opioid Overdose

Neuroleptic Malignant Syndrome

Drug Reaction with Eosinophilia and Systemic Symptoms

Metabolic Changes

Tardive Dyskinesia

Orthostatic Hypotension and Syncope

Falls

Leukopenia, Neutropenia, and Agranulocytosis

Dysphagia

Seizures

Potential for Cognitive and Motor Impairment

Body Temperature Regulation

Anticholinergic (Antimuscarinic) Effects

Hyperprolactinemia

Risks Associated with Combination Treatment with Lithium or Valproate

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adverse Reactions in Patients with Schizophrenia

Patient Exposure

The safety of LYBALVI was evaluated in 1262 patients (18 to 67 years of age) diagnosed with schizophrenia in four double-blind, controlled studies and three long-term safety extension studies of up to 3 years of duration. This experience corresponds to approximately 910 person-years. …

Drug interactions

Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI.

Strong CYP3A4 Inducer

Clinical Implication: | Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan , which may reduce LYBALVI efficacy.

Prevention or Management: | Concomitant use of LYBALVI with strong CYP3A4 inducers is not recommended.

Strong CYP1A2 Inhibitor

Clinical Implication: | Concomitant use of LYBALVI with a strong CYP1A2 inhibitor increases olanzapine AUC and Cmax

, which may increase the risk of LYBALVI adverse reactions.

Prevention or Management: | Consider reducing the dosage of the olanzapine component in LYBALVI when used concomitantly with strong CYP1A2 inhibitors.

CYP1A2 Inducer

Clinical Implication: | Concomitant use of LYBALVI with CYP1A2 inducers decreases olanzapine exposure , which may reduce LYBALVI efficacy.

Prevention or Management: | Consider increasing the dosage of the olanzapine component in LYBALVI when used concomitantly with CYP1A2 inducers.

Diazepam, Alcohol, and Other CNS Acting Drugs

Clinical Implication: | Concomitant use of diazepam, alcohol, or other CNS acting drugs with LYBALVI may potentiate the orthostatic hypotension observed with olanzapine . …

About this medicine

LYBALVI is a combination of olanzapine, an atypical antipsychotic, and samidorphan (as samidorphan L-malate), an opioid antagonist.

Olanzapine is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine. The molecular formula of olanzapine is: C17H20N4S and the molecular weight is 312.44 g/mol. It is a yellow crystalline powder and has pKa values of 7.80 and 5.44. The chemical structure is:

Samidorphan L-malate is morphinan-3-carboxamide, 17-(cyclopropylmethyl)-4, 14-dihydroxy-6-oxo-, (2S)-2-hydroxybutanedioate. The molecular formula of samidorphan L-malate is C21H26N2O4 • C4H6O5 and the molecular weight is 504.54 g/mol. It is a white to off-white crystalline powder and has pKa values of 8.3 (amine) and 10.1 (phenol). The chemical structure is:

LYBALVI is intended for oral administration and is available as film-coated, bilayer tablets in the following strengths: 5 mg/10 mg, 10 mg/10 mg, 15 mg/10 mg, and 20 mg/10 mg of olanzapine and samidorphan (equivalent to 13.6 mg of samidorphan L-malate). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 32ffddd1-4e2b-45d9-9b36-bb730167ec80. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone